NasdaqGS:RGENLife Sciences
How Investors May Respond To Repligen (RGEN) Winning Backing For Its AI-Driven Bioprocessing Platform
In its fourth-quarter 2025 investor letter, Baron Health Care Fund disclosed that it had added Repligen Corporation as a new portfolio holding, citing the company’s strong bioprocessing technology franchise and potential to grow recurring consumable revenues.
The fund also highlighted Repligen’s use of AI for real-time drug production monitoring and its opportunity to benefit from pharmaceutical reshoring, framing these as key drivers of its long-term business opportunity.
We’ll now examine...